Ammonium glycyrrhizinate
Ammonium glycyrrhizinate (Monoammonium glycyrrhizinate) has various pharmacological actions such as anti-inflammatory, antiallergic, antigastriculcer, and antihepatitis activities.
Product Specifications
CAS Number
53956-04-0
Product Name Alternative
Monoammonium glycyrrhizinate; Glycyrrhizic acid (ammonium salt) ; Ammonium glycyrrhizate
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
HAV
Type
Natural Products
Related Pathways
Anti-infection
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Monoammonium_glycyrrhizinate_hydrate.html
Purity
98.31
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1[C@]([C@](CC2)(C)[C@@]3(C)C([C@]([C@@]4(C)CC3)([H])C[C@@](CC4)(C)C(O)=O)=C1)([H])[C@](CC5)(C)[C@]2([H])C([C@H]5O[C@@H](O[C@H](C(O)=O)[C@H]6O)[C@H](O[C@@H]([C@H](O)[C@@H](O)[C@@H]7O)O[C@@H]7C(O)=O)[C@H]6O)(C)C.N
Molecular Formula
C42H65NO16
Molecular Weight
839.96
Precautions
H302, H315, H319, H335
References & Citations
[1]Huang X, et al. Anti-Inflammatory Effects of Monoammonium Glycyrrhizinate on Lipopolysaccharide-Induced Acute Lung Injury in Mice through Regulating Nuclear Factor-Kappa B Signaling Pathway. Evid Based Complement Alternat Med. 2015;2015:272474.|[2]Zhou L, et al. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver. Pharm Biol. 2016;54 (6) :931-7.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Natural Products
Clinical Information
Phase 2
Citation 01
BioRxiv. 2025 Feb 19.|Redox Rep. 2025 Dec;30 (1) :2585221.|3 Biotech. 2020 Aug;10 (8) :369.|ACS Chem Neurosci. 2020 Mar 18;11 (6) :979-993.|Adv Biol (Weinh) . 2025 Jun 4:e00761.|Adv Healthc Mater. 2024 Jan;13 (2) :e2301808.|Adv Sci (Weinh) . 2024 Aug 5:e2404408.|Aging (Albany NY) . 2019 Jul 7;11 (13) :4323-4337.|Behav Brain Res. 2025 May 24:115662.|Biochem Biophys Res Commun. 2021 Feb 12:540:22-28.|bioRxiv. 2025 Feb 19.|BMC Immunol. 2021 May 27;22 (1) :34.|Cell Commun Signal. 2023 May 1;21 (1) :86.|Cell Death Discov. 2024 Jan 17;10 (1) :34.|Cell Prolif. 2020 Jun;53 (6) :e12829.|Cell Prolif. 2024 Nov 20:e13774.|Cell Signal. 2024 Mar:115:111036.|Chem Eng J. 2025 May 1.|CNS Neurosci Ther. 2025 May;31 (5) :e70406.|Drug Des Devel Ther. 2025 Apr 2:19:2503-2517.|EMBO Rep. 2025 Nov 17.|Eur J Med Res. 2025 Oct 9;30 (1) :943.|Eur J Pharmacol. 2025 Oct 5:1004:177971.|Evid Based Complement Alternat Med. 2020 May 31;2020:8653783.|Fish Shellfish Immunol. 2024 Jan:144:109261.|Food Res Int. 2025 Sep 26;222:117620.|Front Cell Dev Biol. 2020 Aug 11;8:713.|Hepatol Commun. 2023 Dec 22;8 (1) :e0350.|Int Immunopharmacol. 2025 Feb 3:149:114192.|Int Immunopharmacol. 2025 Mar 26:150:114294.|J Cell Mol Med. 2025 Nov;29 (21) :e70944.|J Exp Clin Cancer Res. 2024 Apr 4;43 (1) :105.|J Funct Foods. 2021, 104584.|J Inflamm Res. 2025 May 25:18:6735-6748.|Mater Today Bio. 2025 Apr 17:32:101778.|Mol Neurobiol. 2025 May;62 (5) :6070-6087.|Nat Nanotechnol. 2025 May 19.|Neuropharmacology. 2025 Nov 15:279:110617.|Pharm Biol. 2020 Dec;58 (1) :898-904.|Pharmaceuticals (Basel) . 2022 Jan 31;15 (2) :179.|Phytomedicine. 2024 Dec:135:156059.|Phytomedicine. 2025 Jul:142:156713.|Phytomedicine. 2025 Sep:145:157081.|Planta Med. 2021 Jun;87 (7) :538-549.|Res Sq. 2025 Oct 28.|Research Square Preprint. 2022 May.|Research Square Preprint. 2023 Apr 27.|Research Square Print. August 24th, 2022.|Rev Bras Farmacogn. 2023 Jun 28.|Rheumatology (Oxford) . 2025 Aug 13:keaf437.|Sci Rep. 2025 Nov 12;15 (1) :39708.|SSRN. 2025 Jan 15.|SSRN. 2025 Jul 8.|SSRN. 2025 Nov 20.|Toxicol In Vitro. 2025 Oct:108:106104.|World Neurosurg. 2022 Feb:158:e856-e864.|bioRxiv. 2025 Feb 19.|Mediators Inflamm. 2025 Jul 11:2025:2395557.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog